GLP-1 agonist's beyond-the-pill ecosystem opportunity — the extraordinary commercial success of GLP-1 receptor agonists for obesity treatment — semaglutide (Ozempic/Wegovy, Novo Nordisk) and tirzepatide (Mounjaro/Zepbound, Eli Lilly) generating combined revenue exceeding $25 billion in 2023 — creating commercial motivation for beyond-the-pill ecosystem development that...

Market Overview Patient recruitment and engagement are advancing China clinical trials through digital platform and patient-focused approach enabling trial participation expansion. The China Clinical Trials Market transformation enables recruitment through modern approach. Patient recruitment ensure trial success. Current Market Landscape Digital platform connect patient with trial. Social...